As long-term follow-up data from the aforementioned Phase III trials becomes available in the next few years, we will determine whether improved biochemical and local control rates ultimately translate into an overall survival improvement, as seen in the SWOG 8794 trial. The optimal timing of postprostatectomy RT will likely be defined within the next decade, once data from ongoing clinical trials comparing ART and SRT materialize. In the meantime, comparative effectiveness research for this patient population will likely become a major focus of future research efforts. Given the long delays between study conception and the reporting of survival outcomes for Phase III trials in PC, decisions regarding ART versus SRT may be influenced heavily by observational cohort studies, prospective registries and other comparative effectiveness research methods designed to compare the benefits and harms of these two treatment approaches in a usual care setting.
Financial & competing interests disclosure
Research in this publication includes work carried out by the Kimmel Cancer Center, which is supported in part by NCI Cancer Center Support Grant P30 CA56036. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Future Oncol. 2011;7(12):1429-1440. © 2011 Future Medicine Ltd.